NYSE · AVNS

Avanos Medical, Inc.

$24.99 +$0.01 (+0.04%) 1D After hours
Charting by TradingView

Key Metrics

$1.17B
Market cap
—
P/E · TTM
$715.90M
Revenue · TTM
−$74.40M
Net income
EPS · TTM $-1.59
Dividend yield —
Free cash flow $7.50M
Beta · 1Y 0.77
EBITDA · TTM −$28.80M
Gross margin 50.0%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 14
    The stock moved +69.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 14
  • Feb 24
    The stock moved -10.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 24

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.17B
Enterprise value$1.20B
Shares outstanding46.8M
52-wk range$9.30 – $25.49
Avg volume · 20D410.5K
Net cash −$32.60M
Book value / share$16.71
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies
ExchangeNYSE
About Avanos Medical, Inc.
IPO dateOct 21, 2014
Employees2287

Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S1.64
P/FCF156.10
EV/EBITDA—
EV/Sales1.68
Graham №—

Profitability

Gross 50.0%
Operating -9.5%
Net -10.4%
FCF 1.0%
ROE / ROIC -9.2% · -9.1%

Financial Health

Current ratio2.48
Quick ratio1.40
Debt / equity0.13
Debt / EBITDA -3.41
Net cash −$32.60M
Working capital$193.80M

Cash Flow · TTM

Operating CF $36.70M
Capex −$29.20M
Free cash flow $7.50M
Buybacks $2.40M
Dividends paid —
Shareholder yield 0.2%

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

2.3
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings